Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17445095 | 0.95 | GRM5 (0.40) | GRM5MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL2737587 | 0.93 | GRM5 (0.44) | GRM5HPGDHTTL3MBTL1 | |
| SCHEMBL2737589 | 0.91 | HSP90AA1 (0.39) | — | |
| SCHEMBL21279888 | 0.91 | GRM5 (0.40) | GRM5MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL19099927 | 0.91 | GRM5 (0.38) | GRM5KDM4EALDH1A1HTTPRMT5 | |
| SCHEMBL17445017 | 0.91 | FASN (0.36) | GRM5HPGDGAA | |
| SCHEMBL2737767 | 0.91 | GRM5 (0.37) | GRM5MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL2737590 | 0.90 | GRM5 (0.34) | GRM5 | |
| SCHEMBL18022019 | 0.90 | HCRTR1 (0.39) | GRM5HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL19099847 | 0.90 | GRM5 (0.36) | GRM5PARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8980878-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | GRM5 2184/4885MAPK1 4737/4885HPGD 2666/4885 |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | GRM5 4481/4885MAPK1 4565/4885HPGD 2066/4885 |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | GRM5 4481/4885MAPK1 4565/4885HPGD 2066/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | GRM5 4481/4885MAPK1 4565/4885HPGD 2066/4885 |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | GRM5 4481/4885MAPK1 4565/4885HPGD 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.